Genetic Disorders Featuring Neurological Implications and Manifestations: A Comprehensive Review

Naysa Srivastava[1]; Debasmita Sarkar[2]; Shreosee Ghosh[2]; Kunal Vora[2]; Rupak Roy[2*]
[1]Adlai E Stevenson High School, Lincolnshire, Illinois, United States.
[2]SHRM Biotechnologies Pvt. Ltd., Kolkata, West Bengal, India.
Corresponding Author's Email id: rupak@shrmbio.com

Abstract:

Neurological disorders, fundamentally characterized by intricate genetic etiologies, present with a myriad of pathophysiological features and variable progression trajectories. This comprehensive review delves into the molecular genetics and proteinopathies associated with pivotal neurological disorders, namely Huntington's disease, Alzheimer's disease, Multiple Sclerosis (MS), Duchenne Muscular Dystrophy (DMD), Tay-Sachs disease, and Fragile X syndrome. Huntington's disease, precipitated by pathogenic expansions in the HTT gene, is typified by relentless motor deterioration coupled with cognitive regression. Alzheimer's disease, distinguished by neurofibrillary tau tangles and extracellular amyloid-beta plaques, predominantly impairs cognitive faculties and memory, with clinical manifestation typically commencing post-60 years of age. Multiple Sclerosis, an autoimmune demyelinating disorder, results in cumulative neurodegeneration, presenting during early adulthood with episodic relapses and progressive neurological disability. Duchenne Muscular Dystrophy, an X-linked recessive disorder, induces catastrophic muscular atrophy due to dystrophin deficiency, while Tay-Sachs disease, attributable to a deficiency in the enzyme hexosaminidase A, leads to swift neurodegenerative decline during infancy. Fragile X syndrome, underpinned by trinucleotide repeat expansions in the FMR1 gene, precipitates profound cognitive and developmental impairments. This review synthesizes cutting-edge research on the pathological roles of proteins such as huntingtin in Huntington's disease, tau and amyloid-beta in Alzheimer's, myelin basic proteins in MS, dystrophin in DMD, and β-hexosaminidase in Tay-Sachs, underscoring their critical contributions to disease pathogenesis and highlighting their potential as therapeutic targets. Furthermore, recent strides in molecular diagnostics, particularly in DNA-based predictive testing, alongside novel therapeutic strategies, offer a promising horizon for enhanced clinical management and a deeper understanding of these disorders. This review advocates for sustained research efforts into gene-protein interactions, the role of environmental modifiers, and the development of precision therapies aimed at ameliorating patient outcomes and elevating quality of life.

Keywords: Genetic Neurological Disorders; Neurogenetics; Inherited Neurological Diseases; Neurological Manifestations; Genomic Mutations; Neurodevelopmental Disorders

1. INTRODUCTION

Neurological disorders are characterized by dysfunctions in neuronal processing or abnormalities in the brain's structural components and glial cells. Many of these disorders have a substantial genetic component, with genetic mutations or alterations in gene expression often playing a critical role in their aetiology. These genetic factors may either directly cause the condition or contribute to its progression. Typically, such disorders exhibit significant progression after the age of 35, often leading to severe outcomes including reduced lifespan, quadriplegia, and complete paralysis.[14] Certain neurological disorders, such as Huntington's disease, are directly inherited based on

familial history. In contrast, other conditions like multiple sclerosis are not inherited in a classical sense but are associated with genetic mutations that may either be present from birth or develop over an individual's lifetime. Huntington's disease, for example, can lead to seizures, severe spastic episodes, and various other symptoms. Other conditions with significant genetic involvement include Fragile X syndrome, which is linked to Autism Spectrum Disorder, as well as epilepsy[5] and Alzheimer's disease, the latter of which is characterized by progressive cognitive decline. These examples underscore the diverse roles of genetic factors in neurological disorders. Duchenne Muscular Dystrophy, for example, leads to a total loss of motor function[15], while conditions such as Tay-Sachs disease similarly result in paralysis[13].

This review aims to delineate the genetic pathways involved in neurological disorders, focusing on the interplay between gene expression and the onset of symptoms. It will also examine how protein involvement contributes to these manifestations. By elucidating these connections, the review seeks to identify critical genetic causes and enhance understanding of the mechanisms underlying these disorders. In terms of MS and similar conditions, this will explore the possible involvement of genes and other suspected pathways, as they are not known to be directly inherited, but certainly have mutational components and can predispose individuals in the family.[3] The comparison between diseases that have similar onset times and symptoms could provide insights into possible treatment and mortality reduction. This review will focus on obtaining information from research that discusses the impact of proteins produced and the possible control of gene pathways, honing in on the impact of having genetic history or gaining details on more biomarkers that could be involved, improving both treatment and diagnostic protocol. Common factors among neurological disorders with similar physiological impacts may facilitate the identification of shared underlying causes, potentially leading to more effective treatments and improved quality of life for patients across different stages of these conditions. The primary objective of this review is to offer insights into future research directions focused on gene pathway analysis, with a particular emphasis on Huntington's disease. By advancing our understanding of these pathways, the review aims to contribute to the development of targeted therapeutic strategies.

2. OVERVIEW OF DISEASE PHYSIOPATHOLOGY:

Huntington’s disease:

Huntington’s disease is a condition that is characterized by atrophy or decay of neurons, which leads to the loss of voluntary as well as involuntary movement in later stages. It majorly affects the Basal Ganglia, the region responsible for the control of movement. Major symptoms include Chorea, or uncontrollable spasms and movements, which have severe effects on motility and daily life, which is the most common symptom observed. Those who do not develop this have stiffness episodes (akinesia), or fixed positions (dystonia). [9] Difficulty swallowing, gradual paralysis, and other effects- all occur due to the disintegration of neurons in the brain and nervous system, as the HTT protein is involved in synapse functioning, cell cycle regulation, and many other crucial cell survival processes. The pathways will be explored in detail later in this review. [14]

Genetic Basis-The HTT gene is heavily mutated in most cases of the disease, as consistently seen CAG trinucleotide repeats are inherited in an autosomal recessive pattern. This indicates that 50% of all offspring will inherit the disease from an affected mother. An individual with 27-35 CAG repeats will likely not develop the disease themselves but are at risk of passing it on to offspring. Those with 40 or more repeats are considered high risk and most likely will develop the disease, and this form of the gene and/or allele is known as Pathogenic.[9]

Alzheimer's disease:

Major Symptoms- The major symptom associated with this disease is dementia, which occurs due to disrupted signaling in the brain. This can be episodic (more common), or extremely severe, where the individual is unable to form thoughts, communicate, or control extremities. Memory loss is usually the first indicator and a prognostic symptom that can help lead to a diagnosis. [7]

Genetic Basis- This disease does not have any widely agreed upon association with a gene; however, there are confirmed inheritance patterns as well as a genetic predisposition that entails the risks of developing it later in life. There is however evidence of multiple pathways involved in Tau protein production, which greatly affected this disease. Tau tangles or amyloid plaques form on the brain tissue due to increased production of the protein and interfere with neurotransmission. Tau tangles form in nerves or neurons, disrupting synaptic connections and the conduction of impulses.

This is another disease where individuals do not have symptom onset until adulthood, in fact usually around 60 years of age. The median onset age continues to gradually decrease, as more individuals who are middle-aged (40-50) are developing early-onset Alzheimer's due to current environmental factors. This is a major reason for further analysis into the exact gene governing physiological abnormalities, as more individuals develop this with the increased effects of technology on cognition and general brain functioning. [7]

Multiple Sclerosis:

This is a severe, debilitating condition caused by autoimmune responses in the Nervous System, where immune cells attack the Myelin Sheath and cell bodies of neurons (demyelination). This causes cortical atrophy (shrinking of the brain cortex), as connections are severed preventing motor coordination and other activity in the body. Often leading to complete paralysis, the condition is characterized by loss of limb control and even vision due to damage to the Optic nerve. Initial symptoms include vision issues, muscle weakness, spasms, and other motor issues. There are multiple types based on stages of progression, which include remitting and relapsing MS; the most common type initially diagnosed. It is characterised by attacks when the symptoms aggravate, and they are often easily caught. This type progresses to Secondary-progressive MS, in which the attacks become more frequent and harmful. Most cases are diagnosed or show symptoms between the ages of 20 and 40. The lack of a cure and proper treatment makes the condition fatal for those with advanced forms. The need for research into more effective mechanisms, as well as possible genetic involvement, which is discussed in this review.[3]

Duchenne Muscular Dystrophy:

DMD is a condition that leads to muscle degeneration or dystrophy due to the lack of the protein dystrophin, which is discussed later in this review.

Genetic Basis- The condition is inherited through an X-linked pattern, and is more prevalent in males for this reason. Symptoms are noticed by the age of 2 or 3, usually when a child begins walking or moving around with more frequency. Falling often, having trouble with stairs, and weakness, are all early signs. The condition progresses steadily, with most children requiring wheelchairs by 12 years of age. The lack of treatment makes this condition fatal for 100% of cases, as most die of cardiac or pneumonia issues as airway function deteriorates by the age of around 25. [1]

Tay-Sachs disease:

Tay-Sachs disease is a rare, inherited neurodegenerative disorder caused by a deficiency of the enzyme hexosaminidase A. This leads to the accumulation of toxic substances in nerve cells, resulting in progressive neurological deterioration. Symptoms typically appear in infancy and include developmental delay, muscle weakness, and loss of motor skills. Unfortunately, Tay-Sachs is usually fatal in early childhood.
Genetic Basis- It is inherited through an autosomal recessive pattern and effects show quickly. The first signs are extremely subtle and difficult to discern, and it is important to find other diagnosis techniques for this disease. Symptoms of Tay-Sachs disease include hypersensitivity to stimuli, muscle weakness, and other neurological dysfunctions. A cherry-red spot on the retina is commonly observed, although its presence can vary depending on the age of onset and other factors. As the disease progresses, hypotonia and a gradual increase in unresponsiveness are characteristic, often leading to a vegetative state by ages 2 or 3. Late-onset Tay-Sachs, which can manifest between ages 2 and 10, typically progresses less severely but remains fatal, with a vegetative state often occurring by age 15.

The disease is caused by mutations in the HEX A gene, which is crucial for encoding the enzyme hexosaminidase A. This enzyme is vital for normal cellular activity and various essential neurological functions. Although current management is limited to palliative care, research into the HEX A gene and its associated enzymatic functions holds potential for the development of targeted treatments, offering hope for improved therapeutic strategies.[13]

Fragile X Syndrome:

Fragile X Syndromes are conditions associated with great neurological and intellectual disability and often occur alongside conditions like Autism and Epilepsy. They are closely connected to the FMR1 (fragile X messenger ribonucleoprotein 1) gene, which governs cognitive development and reproductive functioning (especially in females). They are inherited in an X-linked dominant pattern, i.e., females are likely to pass the mutated trait on to their offspring due to the FMR1 gene's location on the X chromosome, and males will pass it on to all their offspring. They often affect males more than females, as they do not have any other functional X chromosome to compensate for the one with the mutated gene. Follicle Stimulating Hormone Deficiency and thus "Ovarian Insufficiency" is seen in some females with the condition. This is why hormone replacements are suggested as treatment. Common symptoms that lead to diagnosis include facial structure abnormalities, delayed speech, seizures, intestinal sensitivity, and stool issues. These are mild in nature and may be less noticeable for heterozygous females as their other X chromosome may be compensating for some of the lost functioning. The condition severely impairs cognitive processing due to the crucial role of the FMRP protein in neuronal growth and development. Consequently, diagnosis typically involves a comprehensive range of tests, including genetic blood assays and follow-up examinations, to assess the extent and impact of the disorder.[5]

3. METHODOLOGY

In a comprehensive analysis of relevant studies, this review synthesizes content from various articles and research investigations to provide a broad overview of current advancements aimed at improving treatment options for the neurological conditions previously discussed. Key methodologies for understanding the progression of these conditions include functional Magnetic Resonance Imaging (fMRI) and Electroencephalography (EEG) analysis. These techniques offer significant insights into the brain regions involved, blood flow characteristics, and potential biomarkers.

The ongoing challenge remains the lack of curative treatments for many of these conditions, with progress thus far resulting in a limited reduction in the reliance on palliative care. Predictive DNA testing is another important method used to identify associated genetic mutations and components, a focus of many studies included in this review. Additionally, articles that examined trends within patient groups—such as the prevalence of symptoms and progression patterns—were prioritized to highlight gaps in the current understanding of disease mechanisms.

4. PROTEIN PATHWAYS:

Huntington's disease:

Huntington's disease is caused by mutations in the gene that encodes the huntingtin protein. The Huntingtin Protein is responsible for various suspected tasks, transporting material from the nucleus to the rest of the cell and vice-versa. It is found in all Glial and Neuron cells in the brain, however its exact function is unknown. Many studies have shown the increased presence of this protein in patients with Huntington's, making it a candidate for a potential biomarker or target for treatment. The involvement of glutamine and poly-q tracts in the mHTT (mutant HTT gene) that contributes to this disease is important to note, as those inherited in Huntington's completely alter the structure and functionality of the protein.[14] This can create issues with cognition due to effects on neuronal conduction that remain elusive. One of the only indications of its function is its support for vesicle transport of substances in and outside the cell, allowing linkage between various proteins and the product involved. An important discovery is the lack of significant manifestations of the mutations, except for a slightly smaller brain size, according to a study on Huntington's involvement. This is a major reason why there are very few biomarkers for diagnosis, which are currently limited to measures of Neuronal Degeneration and scans for tracking tissue damage. The protein's pathways may thus be a significant contributor to onset and could provide great insight into treatment, due to their late degradation in higher vertebrates like humans. It has been indicated that targeting only damaged proteins is necessary for efficient and effective treatment due to the crucial effects of the protein's functioning.[16]

Alzheimer's disease:

The disease involves Tau proteins, which are involved in the conduction of impulses across neurons, stabilize microtubules, and allow neurons to escape premature cell death or apoptosis. The abnormal structure and functioning of this protein leads to the formation of aggregates and plaques in various regions of the brain, a characteristic of Alzheimer's onset. The protein's complex pathway and phosphorylation have made it extremely difficult to identify particular targets and genes for potential treatment, which is being heavily studied by many. We can thus say that the "mechanical role of the protein is not clearly understood," as expressed in a paper regarding the role of Tau proteins in Alzheimer's. (Medeiros, R., Baglietto-Vargas, D., & LaFerla, F. M., 2011)
The harnessing of the protein is critical to the treatment of various related conditions and also serves as a factor to identify predisposed individuals more accurately. A recent study has also described the role of the TRIM genes in Tau protein functioning and the possible mutation that could relate to aggregation, making it a promising step towards future study on gene therapies.[11]

Multiple Sclerosis:

The precise causes of Multiple Sclerosis (MS) are not fully understood, though they likely involve a range of proteins, including Myelin Basic Proteins. While pathways related to myelin formation are considered leading candidates for investigation, recent research has shifted focus to other potential factors, such as Epstein-Barr virus infection. The TGF-β gene and its protein have also emerged as significant areas of interest due to their involvement in processes related to disease remission and remyelination following inflammation and neuronal damage. Targeting the TAK

kinase, which is activated in conjunction with TGF-β signaling, could offer a promising therapeutic approach for treating MS by enhancing these reparative processes.[3]

Tay-Sachs disease:

Tay-Sachs disease is closely associated with the deficiency or absence of the enzyme β-hexosaminidase, which is essential for the proper metabolism and storage of gangliosides such as GM2 and GM3 in lysosomes. This enzymatic dysfunction leads to the accumulation of these toxic substances, resulting in premature neuronal cell death and the hallmark symptoms of Tay-Sachs disease.
The condition is primarily caused by mutations in the HEXA gene, which encodes the β-hexosaminidase enzyme. Despite the critical role of the HEXA gene mutation in driving neurodegeneration and eventual paralysis, there is limited understanding of how this mutated gene functions at the molecular level. Current research efforts are focused on elucidating the mechanisms through which the HEX A gene mutation impacts cellular pathways and identifying other molecular products and pathways affected by this mutation.

While the HEX A gene mutation is a central factor in the disease's progression, alterations in additional genes, such as those involved in the Endoplasmic Reticulum-Associated Degradation (ERAD) pathway, have also been implicated. These ERAD factors play a role in the degradation of misfolded proteins, including those resulting from HEX A mutations. Unfortunately, no cure or effective treatment to modify the disease's onset has been discovered to date.[2]

Fragile X Syndrome:

Fragile X syndrome is predominantly attributable to a mutation in the FMR1 gene, as previously indicated, which is responsible for encoding the fragile X mental retardation protein (FMRP). In addition to FMR1, the FXR1 and FXR2 genes, which are part of the Fragile-X Related Gene family (FXR), also play significant roles. The mutation in FMR1 is critically involved in the neurological abnormalities associated with Autism Spectrum Disorder, a prominent symptom of Fragile X syndrome, and is typically observed with early onset.

Abnormalities in FXR1 and FXR2 are associated with additional symptoms, including depression, schizophrenia, and other mental health disorders, primarily due to their involvement in regulating emotional processing. The silencing of the FMR1 gene, which affects mRNA translation at synapses, is a common feature in individuals with Fragile X syndrome. Although the roles of FXR1 and FXR2 in the disease are less well-defined, their involvement is suggested by their contribution to Autism progression and their integration into a "protein-protein network," as highlighted in recent studies.[5]

5. DISCUSSION:

Many of the conditions examined in this review are associated with high mortality rates and currently lack curative treatments. A significant challenge is the limited understanding of the functional implications of various mutated genes or proteins involved in these diseases. Advances in artificial intelligence (AI) and the development of more effective and representative in vitro models, such as mouse cell lines and tissue grafts, have greatly enhanced the capacity to analyze and elucidate complex biological pathways. These technological advancements facilitate deeper insights into disease mechanisms, potentially guiding the development of novel therapeutic strategies.[14] Advancements in testing technologies for biological products and antibodies, particularly those assessing immune responses relevant to conditions such as Multiple Sclerosis (MS), have achieved remarkable accuracy. This progress includes the ability to target specific kinases and fundamental components of cellular signaling and response

pathways. Such developments are highly promising, as they offer the potential to more precisely understand and modulate the underlying mechanisms of these diseases, thereby advancing the prospects for effective therapeutic interventions.[6] Therefore, gene therapy, which involves the eradication of aberrant proteins and the potential correction of mutated genomes, presents a viable treatment approach. This is supported by various studies focusing on delivery mechanisms and the utilization of mRNA technology. Additionally, the identification of biomarkers for these diseases is essential for enhancing treatment efficacy. Early onset of many of these conditions has been exacerbated by environmental and social factors prevalent in various regions worldwide, highlighting the need for timely and accurate diagnostic tools to address these challenges effectively.

CONCLUSION:

The pathways described in this review have significantly altered characteristics, and a common pattern observed in all conditions is a mutated, abnormally functioning protein structure due to these mutations. This is consistent with the cell signalling processes in most cells and also provides us great insight into the extent of involvement of different genes in the pathogenesis of one condition. The identification of all factors possibly out of the scope for today's technology, however there has been significant progress in mapping the proteome and its great impact. Environmental factors are an important consideration in these cases, especially for Alzheimer's, MS and possibly Huntington's disease. The lack of information regarding these effects is due to acceleration of climate change pollution, and changing social dynamics, which are some of the most influential in cognitive and mental development. Study into the effects of environmental factors on the Huntingtin protein is noteworthy, as there is scarce information regarding the protein itself. Research has shown vulnerability and exacerbation of cell death as a result of mutations in this disease as well as in the case of Alzheimers. A course towards protein or genome modification is possibly the most favourable for cures, with the current progress of technology.[12]

References:

1. Cleveland Clinic. (2023, August 23). *Duchenne muscular dystrophy (DMD)*. https://my.clevelandclinic.org/health/diseases/23538-duchenne-muscular-dystrophy-dmd
2. Dersh D, Iwamoto Y, Argon Y. Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation. *Mol Biol Cell*. 2016;27(24):3813-3827. doi:10.1091/mbc.E16-01-0012
3. *Int. J. Mol. Sci.* 2022, *23*(9), 5162; https://doi.org/10.3390/ijms23095162
4. Liu, Y., Li, J., Xie, W., Shen, C., Zhan, R., Ye, Y., ... & He, S. (2022). Identification of NUS1 as a causative gene for dystonia-parkinsonism via phenotype-driven analysis of whole-exome sequencing data. *Neurobiology of Disease, 170*, 105725. https://doi.org/10.1016/j.nbd.2022.105725
5. Majumder, M., Johnson, R. H., & Palanisamy, V. (2020). Fragile X-related protein family: a double-edged sword in neurodevelopmental disorders and cancer. *Critical reviews in biochemistry and molecular biology*, *55*(5), 409–424. https://doi.org/10.1080/10409238.2020.1810621
6. Martinsen V, Kursula P. Multiple sclerosis and myelin basic protein: insights into protein disorder and disease. *Amino Acids*. 2022;54(1):99-109. doi:10.1007/s00726-021-03111-7
7. Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer's disease and related disorders. *CNS Neurosci Ther*. 2011;17(5):514-524. doi:10.1111/j.1755-5949.2010.00177.x
8. Multiple sclerosis. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269. Published April 27, 2022.

9. National Institute of Neurological Disorders and Stroke. Huntington's Disease. National Institutes of Health. Updated September 7, 2023. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease
10. Nopoulos P. C. (2016). Huntington disease: a single-gene degenerative disorder of the striatum. *Dialogues in clinical neuroscience*, *18*(1), 91–98. https://doi.org/10.31887/DCNS.2016.18.1/pnopoulos
11. Penn Medicine. (2023, July 5). *Protein identified as a target for Alzheimer's treatment*. Penn Medicine News. https://www.pennmedicine.org/news/news-releases/2023/july/protein-identified-as-a-target-for-alzheimers-treatment
12. Rahmati, J., Shekari, M., Rahmanian, A., & Ghasemi, M. (2023). Microglial mitochondria quality control in age-associated neurodegenerative diseases: A potential therapeutic target. *Frontiers in Aging Neuroscience*, *15*, 1270226. https://doi.org/10.3389/fnagi.2023.1270226
13. Ramani PK, Parayil Sankaran B. Tay-Sachs Disease. [Updated 2023 Jan 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564432/
14. Schulte, J., & Littleton, J. T. (2011). The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology. *Current trends in neurology*, *5*, 65–78.
15. Venugopal V, Pavlakis S. Duchenne Muscular Dystrophy. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482346/
16. Zhang, S., Cheng, Y. & Shang, H. The updated development of blood-based biomarkers for Huntington's disease. *J Neurol* 270, 2483–2503 (2023). https://doi.org/10.1007/s00415-023-11572-x